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Osteogenesis Imperfecta (OI) is a connective tissue
disorders. There are several types of OI. OI can be autoso-
mal dominant, some cases can be found in recessive by
mosaicism in the parent. The main goal of treatment is to
reduce the incidence of fractures, prevent deformities of
bones and scoliosis, and improve the functional patient.
This is a case of OI given alendronate as an alternative
treatment.
Twin boys babies born in Moewardi Hospital by sectio
caesaria. Baby I and II seemed swollen on both of hand
and leg. Both of the babies appeared to be less active and
limitation of range of motion, with blue sclera. Result of x-
rays, it appeared multiple fractures in extremities and
costae. We diagnosed osteogenesis omperfecta type III,
clinically. We gave alendronate 1 x 1 mg orally, because
sodium pamidronate was not available at that time.
Alendronate were given by thirty to forty five degree posi-
tion. Orthopedic surgeon gave on conservative therapy by
slap. During treatment in hospital, appeared new fractures
in each baby. After giving alendronate therapy for 4
months, the baby I didn’t show new fractures, the baby II
suffered three new fractures. There were no side effect of
alendronate treatment on gastrointestinal. At the aged of
5th month, the patients were given intravenously sodium
pamidronate for 3 days with a dose of 2 mg. Three months
after pamidronate, the baby I didn’t show new fractures,
the baby II suffered one new fracture. Bone mineral
density was not performed in these patients. We conclude
that oral biphosphonate could be alternative treatment for
OI if intravenous biphosphonate is unavailable. It still
needs more reseach regarding to effectiveness of oral
biphosphonate compare to intravenous biphosphonate.
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